Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension.

Sayed CJ, Kirby B, Garg A, Naik HB, Kimball AB, Zouboulis CC, Jemec GBE, Kokolakis G, Ingram JR, Morita A, Deherder D, Crater C, Rolleri RL, Vaux T, Lambert J, Lukowski B, Bechara FG

Open source

DOI: 10.1016/j.jaad.2025.11.031
Published: 2026 Mar
Container: Journal of the American Academy of Dermatology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jaad.2025.11.031,
  title = {Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension.},
  author = {Sayed CJ and Kirby B and Garg A and Naik HB and Kimball AB and Zouboulis CC and Jemec GBE and Kokolakis G and Ingram JR and Morita A and Deherder D and Crater C and Rolleri RL and Vaux T and Lambert J and Lukowski B and Bechara FG},
  year = {2026},
  journal = {Journal of the American Academy of Dermatology},
  doi = {10.1016/j.jaad.2025.11.031},
  url = {https://doi.org/10.1016/j.jaad.2025.11.031}
}

RIS

TY  - JOUR
TI  - Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension.
AU  - Sayed CJ
AU  - Kirby B
AU  - Garg A
AU  - Naik HB
AU  - Kimball AB
AU  - Zouboulis CC
AU  - Jemec GBE
AU  - Kokolakis G
AU  - Ingram JR
AU  - Morita A
AU  - Deherder D
AU  - Crater C
AU  - Rolleri RL
AU  - Vaux T
AU  - Lambert J
AU  - Lukowski B
AU  - Bechara FG
PY  - 2026
JO  - Journal of the American Academy of Dermatology
DO  - 10.1016/j.jaad.2025.11.031
UR  - https://doi.org/10.1016/j.jaad.2025.11.031
ER  -

APA

CJ, S., B, K., A, G., HB, N., AB, K., CC, Z., GBE, J., G, K., JR, I., A, M., D, D., C, C., RL, R., T, V., J, L., B, L., & FG, B. (2026). Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension.. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2025.11.031

Source records

pubmed · retrieved 2026-09-27T16:08:27.330Z